中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

57 records (took 0.052 seconds)

    Systems and methods for cross-linking treatments of an eye
    2.
    发明授权
    Systems and methods for cross-linking treatments of an eye 有权

    公开(公告)号：US10350111B2

    公开(公告)日：2019-07-16

    申请号：US15140184

    申请日：2016-04-27

    Applicant: Avedro, Inc.

    Inventor： Marc D. Friedman ,  Pavel Kamaev ,  Mikhail Smirnov

    IPC: A61N5/06 ,  A61F9/007 ,  A61F9/008

    Abstract: A system for corneal treatment includes a light source that activates cross-linking in at least one selected region of a cornea treated with a cross-linking agent. The light source delivers photoactivating light to the at least one selected region of the cornea according to a set of parameters. The system includes a controller that receives input relating to the cross-linking agent and the set of parameters. The controller includes computer-readable storage media storing: (A) program instructions for determining cross-linking resulting from reactions involving ROS including at least peroxides, superoxides, and hydroxyl radicals, and (B) program instructions for determining cross-linking from reactions not involving oxygen. The controller executes the program instructions to output a calculated amount of cross-linking in the at least one selected region of the cornea. In response to the calculated amount of cross-linking, the light source adjusts at least one value in the set of parameters.

    Systems and methods for monitoring cross-linking activity for corneal treatments
    4.
    发明授权
    Systems and methods for monitoring cross-linking activity for corneal treatments 有权

    公开(公告)号：US10028657B2

    公开(公告)日：2018-07-24

    申请号：US15161302

    申请日：2016-05-23

    Applicant: Avedro, Inc.

    Inventor： Marc D. Friedman

    IPC: G06K9/00 ,  A61B3/14 ,  A61K31/525 ,  A61N5/06 ,  A61B5/00 ,  A61F9/008 ,  A61F9/007

    Abstract: A system for treatment of corneal tissue includes one or more light sources that generate excitation light delivered to corneal tissue treated with a cross-linking agent. The excitation light causes the cross-linking agent to fluoresce by emitting an emission light at a plurality of emission wavelengths. The system includes an image capture system that captures image(s) of the corneal tissue. The image(s) indicate at least two of the emission wavelengths. The system includes a controller that receives the image(s). The controller: identifies each of the at least two emission wavelengths in the image(s); determines, from the image(s), respective characteristics associated separately with each of the at least two emission wavelengths; and provides information relating to cross-linking activity generated by the cross-linking agent in the corneal tissue based on the respective characteristics associated with each of the at least two emission wavelengths.

    SYSTEMS AND METHODS FOR CROSS-LINKING TREATMENTS OF AN EYE
    5.
    发明申请
    SYSTEMS AND METHODS FOR CROSS-LINKING TREATMENTS OF AN EYE 审中-公开
    用于眼睛交联治疗的系统和方法

    公开(公告)号：US20160310319A1

    公开(公告)日：2016-10-27

    申请号：US15140184

    申请日：2016-04-27

    Applicant: Avedro, Inc.

    Inventor： Marc D. Friedman ,  Pavel Kamaev ,  Mikhail Smirnov

    IPC: A61F9/007 ,  A61F9/008

    CPC classification number: A61F9/0079 ,  A61F9/007 ,  A61F9/008 ,  A61F9/00825 ,  A61F2009/00851 ,  A61F2009/00872 ,  A61F2009/00893

    Abstract: A system for corneal treatment includes a light source that activates cross-linking in at least one selected region of a cornea treated with a cross-linking agent. The light source delivers photoactivating light to the at least one selected region of the cornea according to a set of parameters. The system includes a controller that receives input relating to the cross-linking agent and the set of parameters. The controller includes computer-readable storage media storing: (A) program instructions for determining cross-linking resulting from reactions involving ROS including at least peroxides, superoxides, and hydroxyl radicals, and (B) program instructions for determining cross-linking from reactions not involving oxygen. The controller executes the program instructions to output a calculated amount of cross-linking in the at least one selected region of the cornea. In response to the calculated amount of cross-linking, the light source adjusts at least one value in the set of parameters.

    Abstract translation: 用于角膜治疗的系统包括在用交联剂处理的角膜的至少一个选定区域中激活交联的光源。 光源根据一组参数将光活化光传送到角膜的至少一个选定区域。 该系统包括控制器，其接收与交联代理和该组参数相关的输入。 控制器包括计算机可读存储介质，其存储：（A）用于确定由包含至少过氧化物，超氧化物和羟基自由基的ROS的反应产生的交联的程序指令，和（B）用于确定反应的交联的程序说明 涉及氧气。 所述控制器执行所述程序指令以在所述角膜的所述至少一个选定区域中输出计算出的交联量。 响应于所计算的交联量，光源调整该组参数中的至少一个值。

    Eye Therapy System
    6.
    发明申请
    Eye Therapy System 有权
    眼科治疗系统

    公开(公告)号：US20150025440A1

    公开(公告)日：2015-01-22

    申请号：US14507407

    申请日：2014-10-06

    Applicant: Avedro, Inc.

    Inventor： David Muller ,  John Marshall ,  Marc D. Friedman

    IPC: A61N5/06

    CPC classification number: A61N5/062 ,  A61F9/0008 ,  A61F9/013 ,  A61K31/14

    Abstract: Embodiments apply a cross-linking agent to a region of corneal tissue. The cross-linking agent improves the ability of the corneal tissue to resist undesired structural changes. For example, the cross-linking agent may be Riboflavin or Rose Bengal, and the initiating element may be photoactivating light, such as ultraviolet (UV) light. In these embodiments, the photoactivating light initiates cross-linking activity by irradiating the applied cross-linking agent to release reactive oxygen radicals in the corneal tissue. The cross-linking agent acts as a sensitizer to convert O2 into singlet oxygen which causes cross-linking within the corneal tissue. The rate of cross-linking in the cornea is related to the concentration of O2 present when the cross-linking agent is irradiated with photoactivating light. Accordingly, the embodiments control the concentration of O2 during irradiation to increase or decrease the rate of cross-linking and achieve a desired amount of cross-linking.

    Abstract translation: 实施例将交联剂应用于角膜组织的区域。 交联剂改善了角膜组织抵抗不良结构变化的能力。 例如，交联剂可以是核黄素或玫瑰红，并且起始元件可以是光活化的光，例如紫外（UV）光。 在这些实施方案中，光活化光通过照射施加的交联剂以释放角膜组织中的活性氧自由基引发交联活性。 交联剂作为敏化剂将O 2转化成单线态氧，导致角膜组织内的交联。 角膜中的交联速率与交联剂用光活化光照射时存在的O 2浓度有关。 因此，实施例控制照射期间的O 2浓度以增加或降低交联速率并达到所需量的交联。

    FORMULATIONS FOR EYE TREATMENTS
    9.
    发明申请
    FORMULATIONS FOR EYE TREATMENTS 审中-公开

    公开(公告)号：US20200345847A1

    公开(公告)日：2020-11-05

    申请号：US16933059

    申请日：2020-07-20

    Applicant: Avedro, Inc.

    Inventor： Marc D. Friedman ,  Pavel Kamaev ,  Martin Joseph Coffee ,  Rajesh K. Rajpal ,  Alexandra Nicklin

    IPC: A61K41/00 ,  A61K47/18 ,  A61P27/02 ,  A61N5/06 ,  A61K9/00 ,  A61F9/007

    Abstract: Formulations, are used for eye treatments, e.g., cross-linking treatments. For example, a therapeutic formulation includes a photosensitizer and delivery agent(s), wherein the delivery agent(s) include at least one of: anesthetic agent(s), analgesic agent(s), tonicity agent(s), or shear-thinning, or viscosity-increasing agent(s). In another example, a method includes applying preparatory formulation(s) to increase a permeability of a corneal epithelium, and applying therapeutic formulation(s) to the epithelium, where the preparatory formulation(s) include zinc metalloproteinase, copper metalloproteinase, papain, bromelain, actinidin, ficain, N-acetylcysteine, ambroxol, carbocisteine, and/or erdosteine. In yet another example, a method includes applying therapeutic formulation(s) to a corneal epithelium to deliver the therapeutic formulation(s) to a stroma, and applying enhancement formulation(s) to the epithelium in response to applying the therapeutic formulation(s), where: the enhancement formulation(s) remove the therapeutic formulation(s) from the epithelium; close tight junctions of the epithelium; promote oxidation for the therapeutic agent(s); and/or further deliver the therapeutic formulation(s) to the stroma.

Patent Agency Ranking